APA (7th ed.) Citation

Fukushima, M., Miuma, S., Nakao, Y., Sasaki, R., Haraguchi, M., & Miyaaki, H. (2026). Greater Reductions in Hepatitis B Core-Related Antigen Associated with Switching from Entecavir to Tenofovir Alafenamide Compared with Continued Entecavir Therapy: A Retrospective Observational Study. Journal of Clinical Medicine, 15(11), 4021. https://doi.org/10.3390/jcm15114021

Chicago Style (17th ed.) Citation

Fukushima, Masanori, Satoshi Miuma, Yasuhiko Nakao, Ryu Sasaki, Masafumi Haraguchi, and Hisamitsu Miyaaki. "Greater Reductions in Hepatitis B Core-Related Antigen Associated with Switching from Entecavir to Tenofovir Alafenamide Compared with Continued Entecavir Therapy: A Retrospective Observational Study." Journal of Clinical Medicine 15, no. 11 (2026): 4021. https://doi.org/10.3390/jcm15114021.

MLA (9th ed.) Citation

Fukushima, Masanori, et al. "Greater Reductions in Hepatitis B Core-Related Antigen Associated with Switching from Entecavir to Tenofovir Alafenamide Compared with Continued Entecavir Therapy: A Retrospective Observational Study." Journal of Clinical Medicine, vol. 15, no. 11, 2026, p. 4021, https://doi.org/10.3390/jcm15114021.